Impactos de la pérdida de peso inducida por semaglutida y tirzepatida en la estética facial: una revisión integradora de la literatura.
DOI:
https://doi.org/10.66104/d1j34g18Palabras clave:
Obesidad; pérdida de peso; estética facial.Resumen
La búsqueda de un mejor metabolismo y la estética corporal se ha intensificado en los últimos años. Considerando que la obesidad constituye un problema de salud pública mundial, ha habido un aumento significativo en el uso de medicamentos para bajar de peso. Esta revisión tiene como objetivo analizar la evidencia científica sobre los efectos de la pérdida de peso en la estética facial asociada al uso de tirrizepatida y semaglutida. Para el estudio, se consultaron las bases de datos PubMed/MEDLINE, Scopus y Web of Science, y los artículos seleccionados se analizaron descriptiva y comparativamente. Los estudios incluidos demostraron que la pérdida de peso acelerada puede causar repercusiones negativas en la estética facial, como la pérdida de soporte mecánico del tejido y el exceso de piel, favoreciendo la formación de arrugas profundas y alteraciones en las proporciones faciales, características del envejecimiento. Se concluye que los agonistas del receptor de GLP-1 y los agonistas duales de GLP-1/GIP son altamente efectivos en la reducción de peso; Sin embargo, pueden afectar negativamente la autoestima de los pacientes, tanto física como emocionalmente, debido a cambios indeseables en la estética facial, lo que pone de relieve la necesidad de realizar estudios más sistemáticos sobre el tema.
Descargas
Referencias
BAGGETT, A. et al. Cosmetic considerations of semaglutide. Cosmetics, Basel, v. 12, n. 5, p. 221, 2025.
BURKE, O. M.; SA, B.; CESPEDES, D.; TOSTI, A. Dermatologic implications of glucagon-like peptide-1 receptor agonist medications. Skin Appendage Disorders, [S.l.], v. 11, n. 5, p. 416–423, 14 fev. 2025.
CARBONI, A.; MARTINI, O.; MARROQUIN, N. A.; WALLER, J. Natural weight loss or “Ozempic face”: demystifying a social media phenomenon. Journal of Drugs in Dermatology, New York, v. 23, n. 1, p. 1367–1368, 2024.
CATALAMO, L.; DE PONTE, F. S.; DE RINALDIS, D. “Ozempic face”: an emerging drug-related aesthetic concern and its treatment with endotissutal bipolar radiofrequency (RF)—our experience. Journal of Clinical Medicine, Basel, v. 14, n. 15, p. 5269, 2025.
DANESHGARAN, G.; SHAULY, O.; GOULD, D. J. “Ozempic face” in plastic surgery: a systematic review of the literature on GLP-1 receptor agonist mediated weight loss and analysis of public perceptions. Aesthetic Surgery Journal Open Forum, Oxford, v. 7, p. ojaf056, 2025.
EL-AMAWY, H. S. et al. Tirzepatide in dermatology: cutaneous adverse events, emerging therapeutic roles, and cosmetic implications – a comprehensive review. Anais Brasileiros de Dermatologia, Rio de Janeiro, 2026.
HAYKAL, D.; HERSANT, B.; CARTIER, H.; MENINGAUD, J. The role of GLP-1 agonists in esthetic medicine: exploring the impact of semaglutide on body contouring and skin health. Journal of Cosmetic Dermatology, Hoboken, 2024.
LAGO, R. M. et al. Tirzepatide versus GLP-1 receptor agonists in obesity management: metabolic outcomes and clinical implications. Obesity Reviews, Oxford, v. 26, n. 2, e13542, 2025.
RIDHA, Z.; FABI, S. G.; ZUBAIR, R.; DAYAN, S. H. Decoding the implications of glucagon-like peptide-1 receptor agonists on facial aging and accelerated skin aging. Aesthetic Surgery Journal, Oxford, v. 44, n. 11, p. NP809–NP818, nov. 2024.
RUBIO-HERRERA, M. A.; MERA-CARREIRO, S. Weight control treatment in obesity. Medicina Clínica (Barcelona), Barcelona, v. 165, n. 5, p. 107152, nov. 2025.
SEIDEL, M.. Rapid weight loss and facial aging: clinical implications of GLP-1 receptor agonists. Dermatologic Therapy, Hoboken, v. 38, n. 1, e15792, 2025.
SMITS, M. M.; VAN RAALTE, D. H. Safety of semaglutide. Frontiers in Endocrinology, Lausanne, v. 12, p. 645563, 7 jul. 2021. Erratum em: Frontiers in Endocrinology, Lausanne, v. 12, p. 786732, 10 nov. 2021.
Systematic Review on GLP-1RA-Induced Weight Loss and Body Contouring Surgeries. Retrospective association study correlating uso de GLP-1 com aumento de procedimentos estéticos (dados correlacionais e tendências indicadas em literatura científica).
ULLAH, M. I.; TAMANNA, S. Obesidade: impacto clínico, fisiopatologia, complicações e inovações modernas em estratégias terapêuticas. Medicines (Basel), Basel, v. 12, n. 3, p. 19, 28 jul. 2025.
VAMBE, S. D. Semaglutide (Ozempic®): a comprehensive review of its pharmacological properties and clinical applications. South African Pharmaceutical Journal, Johannesburg, v. 91, p. 32–38, 2024.
WORLD HEALTH ORGANIZATION. Obesity and overweight. Geneva: World Health Organization, 2023. Disponível em: https://www.who.int. Acesso em: 20 jan. 2025.
YANG, X. D.; YANG, Y. Y. Clinical pharmacokinetics of semaglutide: a systematic review. Drug Design, Development and Therapy, Auckland, v. 18, p. 2555–2570, 25 jun. 2024.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2026 Mauricio de Sousa Carvalho Reis, Lilian Abreu Sousa Lopes, Ludmila Tolstenko Nogueira, Aniele Carvalho Lacerda , Luciana Tolstenko Nogueira, Antônio Marcolino Ferreira Segundo, Maria Eduarda Mousinho Silva Rodrigues , Kerolayny Lessa de Carvalho Lopes
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Authors who publish in this journal agree to the following terms:
Authors retain copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Creative Commons Attribution License, which permits the sharing of the work with proper acknowledgment of authorship and initial publication in this journal;
Authors are authorized to enter into separate, additional agreements for the non-exclusive distribution of the version of the work published in this journal (e.g., posting in an institutional repository or publishing it as a book chapter), provided that authorship and initial publication in this journal are properly acknowledged, and that the work is adapted to the template of the respective repository;
Authors are permitted and encouraged to post and distribute their work online (e.g., in institutional repositories or on their personal websites) at any point before or during the editorial process, as this may lead to productive exchanges and increase the impact and citation of the published work (see The Effect of Open Access);
Authors are responsible for correctly providing their personal information, including name, keywords, abstracts, and other relevant data, thereby defining how they wish to be cited. The journal’s editorial board is not responsible for any errors or inconsistencies in these records.
PRIVACY POLICY
The names and email addresses provided to this journal will be used exclusively for the purposes of this publication and will not be made available for any other purpose or to third parties.
Note: All content of the work is the sole responsibility of the author and the advisor.
